Vocal Biomarkers Market information: by type (frequency, amplitude, error rate, vocal rise or fall time, phonation time, voice tremor, pitch, others) by indications (psychiatric disorders (depression, Attention Deficit and Disruptive Behavior Disorders, others), neurological disorders (Parkinson's disease (PD), Alzheimer's disease, Huntington's disease, others), Respiratory Disorders, Cardiovascular Disorders, traumatic brain injury (TBI), others), others) by end users (hospitals and clinics, academic and research, others) - Global Forecast till 2027Vocal Biomarkers Market HighlightsThe global vocal biomarkers market is expected to exhibit a strong 14.5% CAGR over the forecast period from 2017 to 2023, according to the latest research report from Market Research Future (MRFR).
Vocal biomarkers are used to diagnose a wide range of diseases, including psychiatric disorders, respiratory disorders, and cardiovascular disorders.
The global vocal biomarkers market is expected to rise to a valuation of USD 2.5 billion by 2023, driven by the increasing demand for strong diagnosis techniques in psychiatry and neurodegenerative disease treatment.Competitive Analysis:Leading players in the global vocal biomarkers market include Cogito Corporation, IBM Corporation, Audio Profiling, Sonde Health, and Beyond Verbal.In July 2019, Winterlight Labs Inc. announced a collaboration with Alector to develop speech-based digital biomarkers for fronto-temporal dementia.Request Free Sample Copy at:https://www.marketresearchfuture.com/sample_request/3933Segmentation:The global vocal biomarkers market is segmented on the basis of type, indications, end users, and region.Based on type, the market has been segmented as frequency, amplitude, error rate, vocal rise or fall time, phonation time, voice tremor, pitch and others.Based on the indications, the market has been segmented as psychiatric disorders (depression, attention deficit and disruptive behavior disorders, others), neurological disorders (Parkinson’s disease (PD), Alzheimer's disease, Huntington's disease, others), respiratory disorders, cardiovascular disorders, traumatic brain injury (TBI), and others.
The share of psychiatric disorders in the vocal biomarkers market is likely to increase over the forecast period, as the role of vocal biomarkers is much more prominent in the diagnosis of psychiatric diseases than in the diagnosis of cardiovascular or respiratory diseases.Based on the end use, the market has been segmented into hospitals and clinics, academic and research, and others.Regional Analysis:North America is likely to dominate the global vocal biomarkers market over the forecast period due to the growing awareness about neurodegenerative diseases, psychotic diseases, and the important role played by vocal biomarkers in identifying these afflictions.
Rapid development of the medical technology sector has led to a growing interest in vocal biomarkers in recent years, as the technology needed for recognizing biomarkers and diagnosing various diseases has become matured over the last few years.
The growing geriatric demographic in North America is likely to be a major driver for the vocal biomarkers market in the region, as leading rates of neurodegenerative diseases are seen among the geriatric demographic.
